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There are extremely important uses for platinum when it comes to the treatment 
of cancers and dementias. One potential therapeutic combines platinum with a structure 
known as phenanthroline. This platinum phenanthroline structure is normally extremely 
water-insoluble, rendering it difficult to study and use in biological systems. The 
Williams’ Biochemistry Laboratory endeavored to find a simpler synthetic pathway for a 
water-soluble phenanthroline product. While unsuccessful in identifying a product as of 
yet, many synthetic pathways have been ruled out, and more hypothetical pathways are 
being formulated for testing.  
Among the strategies analyzed are varying solvent, reagents, apparatus, 
methodology, and temperature in order to coax platinum(II) 1,10-phenanthroline 
dichloride into solution to promote reaction with more water-soluble compounds. Among 
potential future hypotheses are the use of harsher solvents and potentially increasing the 
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Introduction to Platinum Compounds 
 Platinum-based compounds have been used in the treatment of disease and 
advancement of science since the mid-eighteenth century. One of the important chemical 
properties of platinum is its ability to coordinate multiple covalent bonds. Platinum (II) 
can coordinate up to four covalent bonds, whereas the more oxidized version, platinum 
(IV), can maintain six stable bonds, as seen in satraplatin (Johnstone, Park, & Lippard 
2014). 
 While there are a multitude of compounds containing platinum used in medicine, 
many unsuccessful candidates struggle with providing adequate bioavailability. Since 
platinum is a stable heavy metal that coordinates with DNA, it provides considerable 
cytotoxicity in biologically active systems. Medicinal compounds containing platinum 
include drugs used in the treatment of cancers such as cisplatin and oxaliplatin. One of 
the first functions of these drugs was to act as an antineoplastic, preventing or reversing 
the onset of paraneoplastic syndrome in cancer patients (Johnstone, Park, & Lippard, 
2014).  
There are other forms of platinum compounds commonly used in scientific study. 
Platinum compounds frequently used in laboratory settings include tetrachloroplatinate, 
elemental platinum (II) and platinum (IV), and various catalytic salts. Platinum’s modern 
primary use is as a catalyst for a variety of chemical reactions.  
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History and Synthesis of Phenanthroline 
 One family of platinum compounds – those containing or derived from a 1,10-
phenanthroline ligand – have been detailed in the scientific literature since Monatsh 
Blau’s discovery in 1898.  
Figure 1 
 
[Chemical Structure of Platinum (II) 1,10-Phenanthroline] 
 
A refined synthetic method for synthesis of o-phenanthroline was published by 
Breckenridge and Singer (1947). The synthetic process outlined in the mid 20th century 
dictates the use of two successive Skraup reactions to synthesize o-phenanthroline from 
glycerol and o-phenylenediamine (Halcrow & Kermack, 1946).  











[image sourced from Wikipedia article on Skraup reactions. Z.H. Skraup published the 
general model for quinoline synthesis in 1880 manuscript “Eine Synthese des Chinolins.” 
Note that this model is archetypal and is not the Skraup reaction for phenanthroline.] 
At the conclusion of the Skraup reaction, the o-phenanthroline compound can be reacted 
in hydrochloric acid solution under a nitrogen gas atmosphere with tetrachloroplatinate to 
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form Platinum (II) 1,10-phenanthroline dichloride (IUPAC preferred name: 
dichloroplatinum;1,10-phenanthroline) [Pt(II)(phen)](Sun, et al. 2019). 
Properties of Phenanthroline Compounds 
 At the conclusion of a Skraup reaction an aromatic multi-ring structure is formed. 
In the instance of (phen), there are nitrogen atoms at the 1 and 10 positions of the ring 
structure. Phenanthroline derived compounds exhibit varying levels of pKa, solubility, 
and bioactivity. Of particular concern is Pt(II)(phen)Cl2. There is very limited data 
available on the compound. Figure 3 Shows the complex which phenanthroline creates 





Platinum can then form two other coordinate covalent bonds, either with a bidentate 
ligand, or with two separate atoms or molecules.  
Phenanthroline’s appearance on 1H nuclear magnetic resonance spectroscopy 
[NMR] shows 4 groups of peaks. Figure 4 shows standard (phen) spectra (with and 
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without a platinum complex), along with a labeled diagram assigning each proton to a 
peak.  
Figure 4 
[Standard 1,10-Phenanthroline Peak assignments. Adapted from Sun, et al. 2019.] 
 
Due to the symmetry of the molecule along the central line of the platinum, there are only 
four expected peak groups associated with 1,10-phenanthroline. 1H-NMR assists with 
identification of the compounds synthesized or utilized in experiments.  
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Solubility and Bioavailability 
The platinum coordinated (phen) compound discussed above has no known 
remarkable solubility in water. Limited efforts have been documented in synthesizing 
derivative compounds which both include Pt(II)(phen) and also increase the water 
solubility of the compound. Of particular note are alkoxyacetate compounds synthesized 
by Sun, et al. (2019), which show considerably increased bioavailability and cytotoxicity 
when uptake occurs in various tumor cell lines.  Their study showed a maximum 
solubility of 17.5 mg/ml when the coordinated ligand for platinum was alkoxyacetate. 
While these particular compounds have not been reproduced, it shows important promise 
for the phenanthroline ligand.  
 In a review of current literature, no published data has been found for in vitro 
bioavailability of Pt(II)(phen) in mammalian subjects. It is suspected, however, that due 
to the extreme insolubility of the species, bioavailability would approach zero percent.  
Current Research into Phenanthroline 
 A few studies of note demonstrate the potential of o-phenanthroline. Halcrow and 
Kermack (1946) attempted to derive new antimalarial compounds based on 
phenanthroline from quinolines. The study demonstrated that the aromatic rings 
themselves could have substituents added using simple organic chemistry methods. 
However, these o-phenanthroline compounds are distinct from their platinum-coordinated 
derivatives described earlier. While likewise having low solubility in water, they do not 
share the same level of cytotoxicity and chelating ability as the Pt(II)(phen) compounds.  
Barnham, et al (2008) described how Pt(II)(phen)Cl2 could potentially be used to 
prevent aggregation of β-amyloid [Aβ]  into insoluble plaques. By binding to histidine 
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residues in Aβ, Pt(II)(phen) can inhibit essential metal activity and reduce toxicity that 
the plaques cause in synapses. The Pt(II)(phen)Cl2 lowers oxidative stress by inhibiting 
formation of Aβ-Copper(II) complexes which are known to catalyze formation of 
peroxides [Opazo, et al. 2002]. The (phen) ligand shows higher affinity for Aβ than other 
neurological proteins in situ.  
Sun, et al. (2019) utilized structurally similar derivatives of Pt(II)(phen) in order 
to increase solubility of the phenanthroline. They showed that some of these compounds 
were cytotoxic and readily taken in by tumor cell lines in culture, yet less potent than the 
traditional anticancer platinum drugs.  
 There has been a reasonable amount of data published which demonstrates 
Pt(II)(phen) based compounds as potential targeted therapeutics for complex medical 
ailments such as cancers and Alzheimer’s disease. However, the extreme insolubility of 
stock compounds creates a severe inability to utilize findings presented in the literature 
for the advancement of therapeutics. By understanding the implications of a relatively 
easily synthesized yet soluble compound, one can easily understand the need to develop 
and properly characterize such a compound. Various methods have been employed to 







 Among much of the general operating theory of this project in the Williams’ 
Biochemistry Laboratory is that if Pt(II)(phen)Cl2 can undergo a displacement reaction 
with silver oxalate [Ag2(ox), ox = C2O4-2] to create Pt(II)(phen)(ox) and a silver chloride 
precipitate, the oxalate product would likely be appropriately water-soluble. The most 
difficult task has been identifying an appropriate anhydrous solvent which can pull the 
Pt(II)(phen) compound into solution without creating solvation products or creating an 
environment too harsh to isolate the desired product.  
 In order to identify an appropriate solvent, a qualitative solubility survey was 
conducted. A few milligrams of commercially available Pt(II)(phen)Cl2 were dissolved in 
four milliliters each of deionized (DI) water, acetone, chloroform, dichloromethane 
(DCM), and methanol. After 24 hours of stirring in microvials, the DCM and acetonitrile 
appeared to best pull the phenanthroline compound into solution. However, after another 
48 hours without stirring, all compounds appeared to settle back as precipitates. While 
none of these compounds were analyzed using spectroscopic methods to verify that the 
compound had failed to go into solution, this qualitative study demonstrated the difficulty 
which would be present throughout all experiments conducted.  
 As a precursor to discussing individual experiments, Table 1 below shows each 
reagent, solvent, and notes of the reaction sequence which have been attempted for 
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Pt(II)(phen). Table 2 shows each reagent, solvent, and notes of the reaction sequence 
which have been attempted for platinum (II) neocuproine dichloride [Pt(II)(neo)], which 
is sterically and chemically similar to 1,10-phenanthroline. Each experiment will be 
discussed in depth.  
 
Table 1: Summary of Platinum (II) 1,10-Phenanthroline Dichloride Reactions 
Reagent Solvent Notes 
Silver Oxalate  DI Water Yellow resulting solution. 
Light orange precipitate 
after drying.  
Histidine DMSO-d6/D2O Quick exergonic reaction. 
N-Acetyl-L-Methionine DMSO-d6/D2O  
Silver Oxalate DMF Green-yellow solution. 
NMR characterized using 
both D2O and DMSO-d6. 
Silver Oxalate DCM Concentrated under 
vacuum. Crystals knocked 
out with diethyl ether.  
Silver Nitrate DCM Concentrated under 
vacuum. Crystals knocked 
out with diethyl ether. 
 
Table 2: Summary of Platinum (II) Neocuproine Dichloride Reactions 
Reagent Solvent Notes 
Histidine DMSO-d6/D2O Exergonic reaction.  
N-Acetyl-L-Methionine DMSO-d6/D2O Neocuproine compound 
reluctant to enter solution. 
Silver Oxalate  DMSO Unremarkable. 
Silver Oxalate DI Water Unremarkable. 
 
 
Stock Synthesis Reactions 
 Two compounds utilized throughout multiple experiments were synthesized in 
house. The synthetic strategy of Ag2(ox) and Pt(II)(neo)Cl2 are explained below. 
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Silver Oxalate: Although stock bottles of the reagent are available for purchase, it was 
more cost effective to synthesize the compound as needed in the lab. To synthesize 
Ag2(ox), 250 mg of silver nitrate was combined with 125 mg of anhydrous oxalic acid 
with 50 mL of DI water in an amber bottle. The solution was stirred overnight, and 
vacuum filtered. The final product was a white, powdery precipitate. The product was 
stored in an Eppendorf tubule in complete darkness to prevent unwanted photoreactions.  
Platinum (II) Neocuproine Dichloride: The synthesis of the (neo) compound consisted 
of two consecutive reactions. First, 1.25 g of potassium tetrachloroplatinate were 
dissolved in 10 mL of DI water. Once dissolved, 639 mL of DMSO was added. After 
stirring for just under a day, yellow crystals were observed, and the original red color of 
the tetrachloroplatinate was no longer present. This yellow precipitate was gravity filtered 
and dried overnight. This resulting compound, not characterized by NMR, is believed to 
be Pt(II)(DMSO)Cl2. 
 The DMSO compound was used to synthesize the (neo) compound. First, 315 mg 
of the DMSO compound and 156 mg of pure (neo) were brought into solution using 80 
mL of ethanol. This solution was refluxed for one day. After reflux, the resulting solution 
was rotary evaporated, and the resulting solid was dissolved in dichloromethane. This 
new solution was then run through a silica gel column, and a yellow solution was 
collected and dried. This final compound is characterized as Pt(II)(neo)Cl2. 
Silver Oxalate Reactions 
 There are four reactions which utilized silver oxalate as a reagent: three (phen) 
and one (neo). No reactions produced confirmed water-soluble products, but one 
produced a potential success which could not be confirmed by NMR.  
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 In the first two phenanthroline reactions, one used DI water as the solvent, and the 
other used N,N-dimethyl formamide (DMF). The DI water reaction was allowed to stir 
overnight in an amber bottle, and then was gravity filtered, and the resulting solution was 
rotary evaporated. This produced the expected failed reaction, although a minor color 
change in the precipitate from light yellow to light orange was recorded. NMR data did 
not show evidence of any of the expected compounds (reactants or products), and 
therefore the reaction was considered unsuccessful.  
The reaction utilizing DMF, Ag2(ox), and (phen) marked the strongest anhydrous 
solvent used as of yet. A sickly green-yellow color precipitate was formed after the 
solution was allowed to stir overnight. The resultant compound was characterized by 
NMR in both dimethyl sulfoxide-d6 (DMSO-d6) and deuterium oxide (D2O).  
Figure 5: 1H NMR of Silver Oxalate and Platinum (II) 1,10-Phenanthroline in D2O 
 
[This spectra shows the result of reaction between silver oxalate and platinum(II) 1,10-


















































X : parts per Million : 1H
4.5 4.4 4.3 4.2 4.1 4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6
Dichloro Platinum (II) 1,10-Phenanthroline + Oxalic Acid + DMF in D2O
(File: JMY_PtPhen_Oxal_DMF_D2O_Wk_1)
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The NMR data presented shows a variety of peaks set between 2.6-3.1 ppm. These shifts 
are not expected in phenanthroline compounds. Since silver oxalate does not contain any 
additional deuterated protons, it is unclear what compound is present, and whether it has 
any significance in the data.  
 
Figure 6: 1H NMR of Silver Oxalate and Platinum (II) 1,10-Phenanthroline in 
DMSO (8.0-10.0 ppm) 
 
[This spectra shows the upfield shifts in the reaction between silver oxalate and 
platinum(II) 1,10-phenanthroline with DMF as the solvent. Product dissolved in DMSO.] 
 
The data depicted shows peaks consistent with (phen) shielded by the addition of more 
electronegative atoms, such as oxygen on the (ox). All of the peaks exist in the  8.0-10.0 




































X : parts per Million : 1H
9.9 9.8 9.7 9.6 9.5 9.4 9.3 9.2 9.1 9.0 8.9 8.8 8.7 8.6 8.5 8.4 8.3 8.2 8.1























Figure 7: 1H NMR of Silver Oxalate and Platinum (II) 1,10-Phenanthroline in 
DMSO (0.7-3.0 ppm) 
 
[This spectra shows the downfield shift in the reaction between silver oxalate and 
platinum(II) 1,10-phenanthroline with DMF as the solvent. Product dissolved in DMSO.] 
 
The NMR data presented shows a variety of peaks set between 0.7-3.0 ppm. These shifts 
are not expected in (phen) compounds. Since Ag2(ox) does not contain any additional 
deuterated protons, it is unclear what compound is present, and whether it has any 
significance in the data. The large peaks at 1.2 ppm and 2.5 ppm may be a residual 
solvent such as acetone or water.  
The final unsuccessful trials with silver oxalate were with (neo) rather than 
(phen). This reaction in both DI water and DMSO (following the same procedure as for 
phenanthroline) yielded no considerable products, and no identifiable products could be 













X : parts per Million : 1H
3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9 1.8 1.7 1.6 1.5 1.4 1.3 1.2 1.1 1.0 0.9 0.8 0.7
Dichloro Platinum (II) 1,10-Phenanthroline + Oxalic Acid + DMF in DMSO, 0.7-3.0 ppm [part 2]
(File: JMY_PtPhen_Oxal_DMF_DMSO) 
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There was one trial with Ag2(ox) and (phen) which has yielded inconclusive 
results, yet the most likely result is the lack of meaningful reaction. In this reaction, the 
reagents were allowed to stir overnight in dichloromethane. The resulting solution was 
concentrated from 50 mL to 15 mL by rotary vacuum. Then, 5 mL of diethyl ether was 
added, and a sandy yellow precipitate was drawn out of solution. This precipitate was 
gravity filtered, dried overnight, and analyzed via NMR using D2O. The NMR data 
showed no indications of any compounds present in solution and is not included due to its 
lack of remarkability. However, it was observed that the physical characteristics of the 
resultant compound were noticeably different to the original phenanthroline, and the 
compound appeared to go into solution under vortex but would quickly settle when 
unagitated.  
Silver Nitrate Reactions 
 There were a few reactions conducted with silver nitrate, each involving (phen). 
Of particular note was a reaction scheme which paralleled the (phen), (ox), and DCM 
pathway. The method followed for each was identical, with the only alteration being the 
use of silver nitrate instead of silver oxalate. The NMR data once more lacked any 
significant signals. The observation of the resultant compound in preparation for NMR 
showed the yellow product being pulled into solution, and the entire solution becoming 
colorless. It is not confirmed if this product was the intended one, but it is reasonable to 





Amino Acid Reactions 
 A few non-synthetic reactions were conducted to examine the interactions of the 
phenanthroline and neocuproine compounds with methionine [Met] and N-acetyl-L-
histidine [His]. These reactions are important in confirming whether the (neo) and (phen) 
ligands have potential to be biologically active. All four series of reactions were 
conducted in microscale in 80:20 DMSO-d6/D2O. All four produced heat at the addition 
of D2O, as the process of bringing amino acids into solution is an exergonic process. The 
NMR data of all four reactions was collected at multiple time points for comparison and 
compared with the NMR spectra of the stock compounds; at all readings, the instrument 
was calibrated for the DMSO-d6 signal.  
 
Figure 8: 1H NMR for Platinum (II) 1,10-Phenanthroline Dichloride and L-
Histidine in 50:50 DMSO-d6/D2O 
 
 
[The above spectra shows the spectra collected at three different time points for a 



























































X : parts per Million : 1H
11.0 10.0 9.0 8.0 7.0 6.0 5.0
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X : parts per Million : 1H
12.0 11.0 10.0 9.0 8.0 7.0 6.0 5.0
t=7 days 
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Figure 9: 1H NMR for Platinum (II) 1,10-Phenanthroline Dichloride and N-Acetyl-
L-Methionine in 50:50 DMSO-d6/D2O 
 
[The above spectra shows the spectra collected at three different time points for a 
reaction between Pt(II)(phen)Cl2 and (Met).] 
 
Both of the above spectra demonstrate a general shift in chemical pattern over time in 
sealed systems. This suggests that there is a product after three and seven days which was 
not present initially. Most importantly, this NMR data suggests that the (phen) compound 

































X : parts per Million : 1H
























X : parts per Million : 1H


























X : parts per Million : 1H





Discussion of Results 
 One may analyze the results and forget to consider the implications of non-
affirmative results. Of note, there are multiple synthetic pathways that have been ruled 
out as feasible in creation of a viable water-soluble (phen) or (neo) compound. From 
these unsuccessful syntheses, one can extrapolate other potential non-starting points, 
better streamlining the research into synthesis of a final, usable compound. For instance, 
since the qualitative solubility study mentioned earlier yielded similar results for all six 
solvents utilized (DI water, acetonitrile, acetone, chloroform, dichloromethane, 
methanol), it can be reasonable assumed (although not empirically ruled out) that the 
unused solvents would produce similar reactions, or lack thereof.  
 Experiments conducted also verify the potential bioactivity of (phen) and (neo), 
exhibited by the reactions with (His) and (Met). This confirmed reactivity further 
emphasizes the need for research into water-soluble and bioavailable compounds. If these 
compounds can be synthesized, then studies can be undertaken which utilize living 
biological models, such as mice and potentially humans.  
Hypothetical Approaches for Future Work 
 There are a few theoretical approaches which can be considered as potential 
synthetic pathways for future research. Of these, there are two primary concepts two 
examine: using a wider variety of solvents and increasing the oxidation state of the 
platinum.  
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Change the Solvent: There are a variety of harsher solvents and processes which can be 
utilized to force the highly insoluble (phen) into solution. Among these strategies include 
the use of polar aprotic solvents which better facilitate the creation of polar compounds. 
Since water best dissolves polar compounds, polar aprotic solvents like DMF, DMSO, 
and tetrahydrofuran (THF) can help facilitate creation or preservation of net-dipole 
moments in newly synthesized compounds, producing net polarity. Some of these 
solvents may contain residual water, which can be pulled out of the solution using 
molecular sieves.  
 Some of these stronger solvents may require the use of different methods to 
isolate a product than simple filtration or evaporation. Many of these methods are still 
relatively basic isolation techniques, such as extraction using immiscible aqueous and 
organic phase solvents. Alternatively, if the product remains in solution and is not 
precipitated out, it might be possible to produce hydrochloride salts by adding 
hydrochloric acid and ether.  
Oxidize the Platinum: Perhaps one of the more novel methods is to alter the oxidation 
state of the platinum from platinum(II) to platinum(IV). This strategy is derived from the 
synthetic method used in the creation of satraplatin. Platinum (IV) octahedral compounds 
are kinetically inert and act as prodrugs rather than directly as bioactive compounds.  
According to Karmakar et al. (2019), the synthesis of a six-coordinate platinum(IV) 
complex arises from oxidative addition of ligands. Oxidative addition of platinum from 
4-coordination to 5-or-6-coordination has its most difficult step in the activation of the 
platinum(II) into accepting more covalent bonds (Rendina & Puddephatt, 1997). Once 
activated, the platinum can relatively readily accept extra ligands through SN2, concerted, 
19 
and homolytic bond addition mechanisms. A potential product of a successful reaction of 





 To lower potential cytotoxicity and to increase the molecules bioactivity, the two 
chloride ions would be cleaved from the molecule, leaving just the (phen)(ox) ligand to 
act on the proteins. This would result in the original desired product through an indirect 
synthetic pathway which takes advantage of platinum’s multivalent capabilities. It is 
anticipated that polarity of the overall compound would be considerable enough to 





Platinum and phenanthroline related research has been a promising area of 
medical science for over fifty years. Among the common pitfalls of the research into 
these areas is the lack of solubility and bioavailability of the readily synthesized 
compounds, leaving much of the research findings inapplicable to humans for the time 
being. The research of the Williams’ Biochemistry Laboratory attempted to remedy some 
of these pitfalls and create compounds which could be utilized in living biological 
systems to further research applications. While a compound has not at this point been 
synthesized, it is reasonably believed that there are compounds which can be created, and 
multiple potential methods have been identified, ruled out, or hypothesized. Platinum (II) 
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